These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35321517)

  • 1. Efficacy of Disitamab Vedotin in Treating HER2 2+/FISH- Gastric Cancer.
    Dai L; Jin X; Wang L; Wang H; Yan Z; Wang G; Liang B; Huang F; Luo Y; Chen T; Wang Q
    Onco Targets Ther; 2022; 15():267-275. PubMed ID: 35321517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review.
    Qi X; Guo J; Zhou X; Sun L; Lin J; Huang Z; Chen H; Lin L
    Heliyon; 2022 Sep; 8(9):e10581. PubMed ID: 36185140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study.
    Zhou YX; Wang JL; Mu XL; Zhu YJ; Chen Y; Liu JY
    Aging (Albany NY); 2023 Dec; 15(24):15473-15488. PubMed ID: 38147019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disitamab Vedotin: First Approval.
    Deeks ED
    Drugs; 2021 Nov; 81(16):1929-1935. PubMed ID: 34661865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Disitamab vedotin combined with immunotherapy demonstrated excellent efficacy in scrotal Paget's disease with Her-2 overexpression.
    Wang JL; Meng WJ; Hu N; Liu JY
    Front Immunol; 2024; 15():1349033. PubMed ID: 38989283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
    Chen H; Xue L; Liu L; Li P
    J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.
    Zhu K; Chang Y; Zhao D; Guo A; Cao J; Wu C; Guan Y; Ding S
    Front Pharmacol; 2024; 15():1355081. PubMed ID: 38455962
    [No Abstract]   [Full Text] [Related]  

  • 8. Case report: Successful treatment of advanced urothelial carcinoma with trophoblastic differentiation using Tislelizumab and Disitamab vedotin.
    Han Y; Zhou Y; Wu Z; Liu L; Han C
    Heliyon; 2024 Oct; 10(19):e38518. PubMed ID: 39397900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE.
    Jiang J; Li S; Shan X; Wang L; Ma J; Huang M; Dong L; Chen F
    Toxicol Lett; 2020 May; 324():30-37. PubMed ID: 31877330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report.
    Wu Q; He L; Luo J; Jin W; Xu Y; Wang C
    Oncol Lett; 2022 Oct; 24(4):339. PubMed ID: 36039062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review.
    Li Y; Zhang J; Cai Z; Gao X; Zhang L; Lu Z; Wang X; Yu P; Li J; Fang F
    Front Oncol; 2023; 13():1286392. PubMed ID: 38074635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report.
    Zhou JH; Yi QJ; Li MY; Xu Y; Dong Q; Wang CY; Liu HY
    World J Clin Cases; 2024 Feb; 12(4):820-827. PubMed ID: 38322681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete response to disitamab vedotin in HER2-low metastatic endometrial carcinoma: a case report and review of the literature.
    Feng H; Bi S; Sun S; Yang H; Zhou H; Mao J; Li N; Yang F
    Front Oncol; 2024; 14():1367140. PubMed ID: 39351350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report.
    Qu F; Liu Q; Lu R; Li W
    Front Oncol; 2023; 13():1245701. PubMed ID: 37711199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.
    Hu Y; Zhu Y; Wei X; Tang C; Zhang W
    Drugs Today (Barc); 2022 Oct; 58(10):491-507. PubMed ID: 36305543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disitamab Vedotin plus anti-PD-1 antibody show good efficacy in refractory primary urethral cancer with low HER2 expression: a case report.
    Zheng Y; Xue YY; Zhao YQ; Chen Y; Li ZP
    Front Immunol; 2023; 14():1254812. PubMed ID: 37901233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.
    Huang H; Zhang Y; Chen Z; Zeng X; Hu Z; Yang C
    Heliyon; 2023 Apr; 9(4):e15157. PubMed ID: 37123934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report.
    Chen ZL; Zhao A; Li P; Zhang M; Yang J; Zhang L; Zhao X; Yang J; Wang L
    Oncol Lett; 2018 Oct; 16(4):4614-4620. PubMed ID: 30214596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study.
    Zhao H; Xu Z; Li C; Xu T; Zhang J; Jiao J; Yang B; Qin R; Yang L; Qin W; Jing Y
    Adv Ther; 2024 Feb; 41(2):857-866. PubMed ID: 38048019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil.
    Xu Z; Hu C; Chen S; Zhang C; Yu J; Wang X; Lv H; Cheng X
    Cancer Manag Res; 2019; 11():4905-4915. PubMed ID: 31213909
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.